To our knowledge this is the first demonstration that glyco-engineering of an anti-PD-L1 antibody results in increased CD8 T cell activation conferring to an enhanced CD8 T cell cytotoxicity against tumor cells. This evidence concerns the gene CD8A and neoplasm.